

March 18, 2025

Patented Medicine Prices Review Board
Standard Life Centre, Box L40
333 Laurier Avenue West, Suite 1400
Ottawa, Ontario K1P 1C1

Dear PMPRB,

I am writing to express our support for the revised guidelines proposed by the Patented Medicine Prices Review Board (PMPRB). These measures ensure that drug prices are monitored, preventing excessive costs that could burden consumers and the healthcare system.

The high cost of patented medicines has been a growing concern for Canadians, and the new PMPRB guidelines address this issue by implementing price controls and fostering transparency in the pricing process. By aligning drug prices with select countries, these guidelines will help prevent excessive pricing and protect public interests and the healthcare system as a whole. The new guidelines will contribute to the overall health and well-being of Canadians.

I commend the PMPRB for its efforts to protect Canadians from excessive drug prices and to promote fair and sustainable healthcare system. I support the PMPBR adopting these guidelines and continuing working toward fair pricing for all Canadians.

Sincerely,



Mauro Chies
Chief Executive Officer
pan-Canadian Pharmaceutical Alliance